Hsp90 Modulation for the Treatment of Alzheimer's Disease

Advances in Pharmacology

Volumn 64, Issue , 2012, Pages 1-25

  Zhao, Huiping ^a   Michaelis, Mary L ^a   Blagg, Brian S J ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

Cytoprotective; Heat shock response; Hsp90; Neuroprotection; Prosurvival; Protein folding

Indexed keywords

ACETYLCHOLINESTERASE; AEG 3482; AMYLOID BETA PROTEIN; BETA SECRETASE; CELASTROL; CHAPERONE; CURCUMIN; CYCLIN DEPENDENT KINASE 4; EC 102; EPIGALLOCATECHIN GALLATE; GEDUNIN; GELDANAMYCIN; HEAT SHOCK PROTEIN 40; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HEAT SHOCK TRANSCRIPTION FACTOR 1; INDAZOL 4 ONE; ISOXAZOLE; ITZ 1; NOVOBIOCIN; PROTEIN KINASE B; PU 3; PURINE; RADICICOL; RAF PROTEIN; SILIBININ; SNX 2112; STRESS ACTIVATED PROTEIN KINASE; SURVIVIN; TANESPIMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTICLE; HEAT SHOCK; HOMEOSTASIS; HUMAN; HUNTINGTON CHOREA; IMMUNOPRECIPITATION; KENNEDY DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN PHOSPHORYLATION; SURFACE PLASMON RESONANCE; TAUOPATHY;

EID: 84864301098     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-394816-8.00001-5     Document Type: Chapter

References (110)

1. Abenavoli L., Capasso R., Milic N., Capasso F. Milk thistle in liver diseases: past, present, future. Phytotherapy Research 2010, 24(10):1423-1432.
2. Adachi H., Katsuno M., Waza M., Minamiyama M., Tanaka F., Sobue G. Heat shock proteins in neurodegenerative diseases: Pathogenic roles and therapeutic implications. International Journal of Hyperthermia 2009, 25(8):647-654.
3. Allison A.C., Cacabelos R., Lombardi V.R.M., Alvarez X.A., Vigo C. Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2001, 25(7):1341-1357.
4. Ansar S., Burlison J.A., Hadden M.K., Yu X.M., Desino K.E., Bean J., et al. A non-toxic Hsp90 inhibitor protects neurons from A beta-induced toxicity. Bioorganic & Medicinal Chemistry Letters 2007, 17(7):1984-1990.
5. Arai T., Hasegawa M., Akiyama H., Ikeda K., Nonaka T., Mori H., et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochemical and Biophysical Research Communications 2006, 351(3):602-611.
6. Auluck P.K., Chan H.Y.E., Trojanowski J.Q., Lee V.M.Y., Bonini N.M. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 2002, 295(5556):865-868.
7. Ballinger C.A., Connell P., Wu Y.X., Hu Z.Y., Thompson L.J., Yin L.Y., et al. Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions. Molecular and Cellular Biology 1999, 19(6):4535-4545.
8. Baum L., Lam C.W.K., Cheung S.K.K., Kwok T., Lui V., Tsoh J., et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. Journal of Clinical Psychopharmacology 2008, 28(1):110-113.
9. Biamonte M.A., Van de Water R., Arndt J.W., Scannevin R.H., Perret D., Lee W.C. Heat shock protein 90: Inhibitors in clinical trials. Journal of Medicinal Chemistry 2010, 53(5). (Vol. 53, p. 3, 2010), 2332-2332.
10. Blagg B.S.J., Kerr T.A. Hsp90 inhibitors: Small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation. Medicinal Research Reviews 2006, 26(3):310-338.
11. Bolton D.C., McKinley M.P., Prusiner S.B. Identification of a protein that purifies with the scrapie prion. Science 1982, 218(4579):1309-1311.
12. Bracher A., Hartl F.U. Hsp90 structure: When two ends meet. Nature Structural & Molecular Biology 2006, 13(6):478-480.
13. Brandt G.E.L., Blagg B.S.J. Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases. Current Topics in Medicinal Chemistry 2009, 9(15):1447-1461.
14. Brandt G.E.L., Schmidt M.D., Prisinzano T.E., Blagg B.S.J. Gedunin, a novel Hsp90 inhibitor: Semisynthesis of derivatives and preliminary structure-activity relationships. Journal of Medicinal Chemistry 2008, 51(20):6495-6502.
15. Brown I.R. Heat shock proteins and protection of the nervous system. Stress responses in biology and medicine: Stress of life in molecules, cells, organisms, and psychosocial ommunities 2007, Wiley-Blackwell, Malden, (Vol. 1113, pp. 147-158). P. Csermely, T. Korcsmaros, K. Sulyok (Eds.).
16. Bruijn L.I., Houseweart M.K., Kato S., Anderson K.L., Anderson S.D., Ohama E., et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 1998, 281(5384):1851-1854.
17. Calamini B., Silva M.C., Madoux F., Hutt D.M., Khanna S., Chalfant M.A., et al. Small-molecule proteostasis regulators for protein conformational diseases. Nature Chemical Biology 2012, 8(2):185-196.
18. Chiosis G., Timaul M.N., Lucas B., Munster P.N., Zheng F.F., Sepp-Lorenzino L., et al. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chemistry & Biology 2001, 8(3):289-299.
19. Conde R., Belak Z.R., Nair M., O'Carroll R.F., Ovsenek N. Modulation of Hsf1 activity by novobiocin and geldanamycin. Biochemistry and Cell Biology-Biochimie Et Biologie Cellulaire 2009, 87(6):845-851.
20. Connell P., Ballinger C.A., Jiang J.H., Wu Y.X., Thompson L.J., Hohfeld J., et al. The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nature Cell Biology 2001, 3(1):93-96.
21. Cuervo A.M., Dice J.F. Age-related decline in chaperone-mediated autophagy. Journal of Biological Chemistry 2000, 275(40):31505-31513.
22. Dickey C.A., Kamal A., Lundgren K., Klosak N., Bailey R.M., Dunmore J., et al. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. Journal of Clinical Investigation 2007, 117(3):648-658.
23. DiFiglia M., Sapp E., Chase K.O., Davies S.W., Bates G.P., Vonsattel J.P., et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997, 277(5334):1990-1993.
24. Dou F., Netzer W.J., Tanemura K., Li F., Hartl F.U., Takashima A., et al. Chaperones increase association of tau protein with microtubules. Proceedings of the National Academy of Sciences of the United States of America 2003, 100(2):721-726.
25. Ehrnhoefer D.E., Bieschke J., Boeddrich A., Herbst M., Masino L., Lurz R., et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nature Structural & Molecular Biology 2008, 15(6):558-566.
26. Evans C.G., Wisen S., Gestwicki J.E. Heat shock proteins 70 and 90 inhibit early stages of amyloid beta-(1-42) aggregation in vitro. Journal of Biological Chemistry 2006, 281(44):33182-33191.
27. Fernandez J.W., Rezai-Zadeh K., Obregon D., Tan J. EGCG functions through estrogen receptor-mediated activation of ADAM10 in the promotion of non-amyloidogenic processing of APP. Febs Letters 2010, 584(19):4259-4267.
28. Gallo K.A. Targeting HSP90 to halt neurodegeneration. Chemistry & Biology 2006, 13(2):115-116.
29. Ganguli M., Chandra V., Kamboh M.I., Johnston J.M., Dodge H.H., Thelma B.K., et al. Apolipoprotein E polymorphism and Alzheimer disease-The Indo-US cross-national dementia study. Archives of Neurology 2000, 57(6):824-830.
30. Gazak R., Walterova D., Kren V. Silybin and silymarin - new and emerging applications in medicine. Current Medicinal Chemistry 2007, 14(3):315-338.
31. Giommarelli C., Zuco V., Favini E., Pisano C., Dal Piaz F., De Tommasi N., et al. The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition. Cellular and Molecular Life Sciences 2010, 67(6):995-1004.
32. Glenner G.G., Wong C.W. Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochemical and Biophysical Research Communications 1984, 120(3):885-890.
33. Golde T.E., Schneider L.S., Koo E.H. Anti-A beta therapeutics in Alzheimer's disease: The need for a paradigm shift. Neuron 2011, 69(2):203-213.
34. Grundke-Iqbal I., Iqbal K., Tung Y.C., Quinlan M., Wisniewski H.M., Binder L.I. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proceedings of the National Academy of Sciences of the United States of America 1986, 83(13):4913-4917.
35. Hamaguchi T., Ono K., Yamada M. Curcumin and Alzheimer's disease. [Review]. CNS Neuroscience & Therapeutics 2010, 16(5):285-297.
36. Hardy J.A., Higgins G.A. Alzheimer's disease: The amyloid cascade hypothesis. Science 1992, 256(5054):184-185.
37. Hatcher H., Planalp R., Cho J., Tortia F.M., Torti S.V. Curcumin: From ancient medicine to current clinical trials. Cellular and Molecular Life Sciences 2008, 65(11):1631-1652.
38. Hieronymus H., Lamb J., Ross K.N., Peng X.P., Clement C., Rodina A., et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 2006, 10(4):321-330.
39. Hooper D.C., Wolfson J.S., McHugh G.L., Winters M.B., Swartz M.N. Effects of novobiocin, coumermycin A1, clorobiocin, and their analogs on Escherichia coli DNA gyrase and bacterial growth. Antimicrobial agents and chemotherapy 1982, 22(4):662-671.
40. Jiang J.H., Ballinger C.A., Wu Y.X., Dai Q., Cyr D.M., Hohfeld J., et al. CHIP is a U-box-dependent E3 ubiquitin ligase-identification of Hsc70 as a target for ubiquitylation. Journal of Biological Chemistry 2001, 276(46):42938-42944.
41. Jinwal U.K., Trotter J.H., Abisambra J.F., Koren J., Lawson L.Y., Vestal G.D., et al. The Hsp90 kinase co-chaperone Cdc37 regulates yau stability and phosphorylation dynamics. Journal of Biological Chemistry 2011, 286(19):16976-16983.
42. Kamath S.G., Chen N., Xiong Y., Wenham R., Apte S., Humphrey M., et al. Gedunin, a novel natural substance, inhibits ovarian cancer cell proliferation. International Journal of Gynecological Cancer 2009, 19(9):1564-1569.
43. Kim J., Lee H.J., Lee K.W. Naturally occurring phytochemicals for the prevention of Alzheimer's disease. Journal of Neurochemistry 2010, 112(6):1415-1430.
44. Kim Y.S., Alarcon S.V., Lee S., Lee M.J., Giaccone G., Neckers L., et al. Update on Hsp90 inhibitors in clinical trial. Current Topics in Medicinal Chemistry 2009, 9(15):1479-1492.
45. Kimura H., Yukitake H., Suzuki H., Tajima Y., Gomaibashi K., Morimoto S., et al. The chondroprotective agent ITZ-1 inhibits interleukin-1 beta-induced matrix metalloproteinase-13 production and suppresses nitric oxide-induced chondrocyte death. Journal of Pharmacological Sciences 2009, 110(2):201-211.
46. Kimura H., Yukitake H., Tajima Y., Suzuki H., Chikatsu T., Morimoto S., et al. ITZ-1, a client-selective Hsp90 inhibitor, efficiently induces heat shock factor 1 activation. Chemistry & Biology 2010, 17(1):18-27.
47. Kopito R.R., Ron D. Conformational disease. Nature Cell Biology 2000, 2(11):E207-E209.
48. Krukenberg K.A., Street T.O., Lavery L.A., Agard D.A. Conformational dynamics of the molecular chaperone Hsp90. Quarterly Reviews of Biophysics 2011, 44(2):229-255.
49. Kumar P., Ambasta R.K., Veereshwarayya V., Rosen K.M., Kosik K.S., Band H., et al. CHIP and HSPs interact with beta-APP in a proteasome-dependent manner and influence A beta metabolism. Human Molecular Genetics 2007, 16(7):848-864.
50. Kutney J.P., Hewitt G.M., Kurihara T., Salisbury P.J., Sindelar R.D., Stuart K.L., et al. Cyto-toxic diterpenes triptolide, tripdiolide, and cyto-toxic triterpenes from tissue cultures of Tripterygium wilfodii. Canadian Journal of Chemistry-Revue Canadienne De Chimie 1981, 59(17):2677-2683.
51. Lakshmi V., Singh N., Shrivastva S., Mishra S.K., Dharmani P., Mishra V., et al. Gedunin and Photogedunin of Xylocarpus granatum show significant anti-secretory effects and protect the gastric mucosa of peptic ulcer in rats. Phytomedicine 2010, 17(8-9):569-574.
52. Lamb J. Innovation-The connectivity map: A new tool for biomedical research. Nature Reviews Cancer 2007, 7(1):54-60.
53. Lamb J., Crawford E.D., Peck D., Modell J.W., Blat I.C., Wrobel M.J., et al. The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease. Science 2006, 313(5795):1929-1935.
54. Lau L.-F., Schachter J.B., Seymour P.A., Sanner M.A. Tau protein phosphorylation as a therapeutic target in Alzheimer's disease. Current Topics in Medicinal Chemistry Hilversum, Netherlands 2002, 2(4):395-415.
55. Lee V.M.Y., Goedert M., Trojanowski J.Q. Neurodegenerative tauopathies. Annual Review of Neuroscience 2001, 24:1121-1159.
56. Li Y.Y., Zhang T., Jiang Y.Q., Lee H.F., Schwartz S.J., Sun D.X. (-)-Epigallocatechin-3-gallate inhibits Hsp90 function by impairing Hsp90 association with cochaperones in pancreatic cancer cell line Mia Paca-2. Molecular Pharmaceutics 2009, 6(4):1152-1159.
57. Lu P., Mamiya T., Lu L.L., Mouri A., Niwa M., Hiramatsu M., et al. Silibinin attenuates amyloid beta(25-35) peptide-induced memory impairments: Implication of inducible nitric-oxide synthase and tumor necrosis factor-alpha in mice. Journal of Pharmacology and Experimental Therapeutics 2009, 331(1):319-326.
58. Lu P., Mamiya T., Lu L.L., Mouri A., Zou L.B., Nagai T., et al. Silibinin prevents amyloid beta peptide-induced memory impairment and oxidative stress in mice. British Journal of Pharmacology 2009, 157(7):1270-1277.
59. Lu Y.M., Ansar S., Michaelis M.L., Blagg B.S.J. Neuroprotective activity and evaluation of Hsp90 inhibitors in an immortalized neuronal cell line. Bioorganic & Medicinal Chemistry 2009, 17(4):1709-1715.
60. Lund J., Tedesco P., Duke K., Wang J., Kim S.K., Johnson T.E. Transcriptional profile of aging in C-elegans. Current Biology 2002, 12(18):1566-1573.
61. Luo W.J., Dou F., Rodina A., Chip S., Kim J., Zhao Q., et al. Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(22):9511-9516.
62. Luo W.J., Sun W.L., Taldone T., Rodina A., Chiosis G. Heat shock protein 90 in neurodegenerative diseases. Molecular Neurodegeneration 2010, 5.
63. Marathe S.A., Dasgupta I., Gnanadhas D.P., Chakravortty D. Multifaceted roles of curcumin: Two sides of a coin!. Expert Opinion on Biological Therapy 2011, 11(11):1485-1499.
64. Marcu M.G., Chadli A., Bouhouche I., Catelli M., Neckers L.M. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. Journal of Biological Chemistry 2000, 275(47):37181-37186.
65. Marcu M.G., Schulte T.W., Neckers L. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. Journal of the National Cancer Institute 2000, 92(3):242-248.
66. Matts R.L., Brandt G.E.L., Lu Y.M., Dixit A., Mollapour M., Wang S.Q., et al. A systematic protocol for the characterization of Hsp90 modulators. Bioorganic & Medicinal Chemistry 2011, 19(1):684-692.
67. McClellan A.J., Frydman J. Molecular chaperones and the art of recognizing a lost cause. Nature Cell Biology 2001, 3(2):E51-E53.
68. Meacham G.C., Patterson C., Zhang W.Y., Younger J.M., Cyr D.M. The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation. Nature Cell Biology 2001, 3(1):100-105.
69. Misra S., Verma M., Mishra S.K., Srivastava S., Lakshmi V., Misra-Bhattacharya S. Gedunin and photogedunin of xylocarpus granatum possess antifilarial activity against human lymphatic filarial parasite Brugia malayi in experimental rodent host. Parasitology Research 2011, 109(5):1351-1360.
70. Morimoto R.I. Proteotoxic stress and inducible chaperone networks in neurodegenerative disease and aging. Genes & Development 2008, 22(11):1427-1438.
71. Morris M., Maeda S., Vossel K., Mucke L. The many faces of tau. Neuron 2011, 70(3):410-426.
72. Neef D.W., Turski M.L., Thiele D. Modulation od heat shock transcription factor 1 as a therapeutic target for small molecule intervention in neurodegenerative disease. PLos Biology 2010, 8(1):e1000291.
73. Neef D.W., Jaeger A.M., Thiele D.J. Heat shock transcription factor 1 as a therapeutic target in neurodegenerative diseases. Nature Reviews 2011, 10(12):930-944.
74. Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006, 314(5796):130-133.
75. Oddo S., Caccamo A., Tseng B., Cheng D., Vasilevko V., Cribbs D.H., et al. Blocking A beta(42) accumulation delays the onset and progression of tau pathology via the C terminus of heat shock protein70-interacting protein: A mechanistic link between A beta and tau pathology. Journal of Neuroscience 2008, 28(47):12163-12175.
76. Omar S., Godard K., Ingham A., Hussain H., Wongpanich V., Pezzuto J., et al. Antimalarial activities of gedunin and 7-methoxygedunin and synergistic activity with dillapiol. Annals of Applied Biology 2003, 143(2):135-141.
77. Ono K., Hasegawa K., Naiki H., Yamada M. Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. Journal of Neuroscience Research 2004, 75(6):742-750.
78. Palermo C.M., Westlake C.A., Gasiewicz T.A. Epigallocatechin gallate inhibits aryl hydrocarbon receptor gene transcription through an indirect mechanism involving binding to a 90kDa heat shock protein. Biochemistry 2005, 44(13):5041-5052.
79. Patterson K.R., Ward S.M., Combs B., Voss K., Kanaan N.M., Morfini G., et al. Heat shock protein 70 prevents both tau aggregation and the inhibitory effects of preexisting tau aggregates on fast axonal transport. Biochemistry 2011, 50(47):10300-10310.
80. Petrucelli L., Taylor J., Kehoe K., Lewis J., McGowan E., Snyder H., et al. Chip and HSP70 regulate tau ubiquitination, degradation and aggregation. Neurobiology of Aging 2004, 25:S419-S420.
81. Powers E.T., Morimoto R.I., Dillin A., Kelly J.W., Balch W.E. Biological and chemical approaches to diseases of proteostasis deficiency. Annual Review of Biochemistry 2009, 78:959-991.
82. Queen B.L., Tollefsbol T.O. Polyphenols and aging. Current Aging Science 2010, 3(1):34-42.
83. Richter K., Buchner J. Hsp90: Twist and fold. Cell 2006, 127(2):251-253.
84. Salehi A.H., Morris S.J., Ho W.C., Dickson K.M., Doucet G., Milutinovic S., et al. AEG3482 is an antiapoptotic compound that inhibits Jun kinase activity and cell death through induced expression of heat shock protein 70. Chemistry & Biology 2006, 13(2):213-223.
85. Salminen A., Ojala J., Kaarniranta K., Hiltunen M., Soininen H. Hsp90 regulates tau pathology through co-chaperone complexes in Alzheimer's disease. Progress in Neurobiology 2011, 93(1):99-110.
86. Santagata S., Xu Y., Wijeratne E.M.K., Kontnik R., Rooney C., Perley C.C., et al. Using the heat-shock response to discover anticancer compounds that target protein homeostasis. ACS Chemical Bilogy 2012, 7(2):340-349.
87. Shamovsky I., Gershon D. Novel regulatory factors of HSF-1 activation: Facts and perspectives regarding their involvement in the age-associated attenuation of the heat shock response. Mechanisms of Ageing and Development 2004, 125(10-11):767-775.
88. Sherman M.Y., Gabai V.L., Meriin A.B., Yaglom J.A. Regulation of stress-kinases, JNK and p38, by Hsp70: Implication in cell protection. Cell Stress & Chaperones 2000, 5(5). 487-487.
89. Silva M.C., Fox S., Beam M., Thakkar H., Amaral M.D., Morimoto R.I. A genetic screening strategy identifies novel regulators of the proteostasis network. PLoS Genetics 2011, 7(12):e1002438.
90. Singh M., Arseneault M., Sanderson T., Murthy V., Ramassamy C. Challenges for research on polyphenols from foods in Alzheimer's disease: Bioavailability, metabolism, and cellular and molecular mechanisms. Journal of Agricultural and Food Chemistry 2008, 56(13):4855-4873.
91. Sittler A., Lurz R., Lueder G., Priller J., Hayer-Hartl M.K., Hartl F.U., et al. Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease. Human Molecular Genetics 2001, 10(12):1307-1315.
92. Soto C., Estrada L.D. Protein misfolding and neurodegeneration. Archives of Neurology 2008, 65(2):184-189.
93. Spillantini M.G., Goedert M. Tau protein pathology in neurodegenerative diseases. Trends in Neurosciences 1998, 21(10):428-433.
94. Subapriya R., Nagini S. Medicinal properties of neem leaves: A review. Current Medicinal Chemistry. Anti-Cancer Agents 2005, 5(2):149-156.
95. Sundarasivarao B., Nazma, Madhusudhanarao J. Antifungal activity of gedunin. Current Science 1977, 46(20):714-716.
96. Taipale M., Jarosz D.F., Lindquist S. HSP90 at the hub of protein homeostasis: Emerging mechanistic insights. Nature Reviews Molecular Cell Biology 2010, 11(7):515-528.
97. Taldone T., Chiosis G. Purine-scaffold Hsp90 inhibitors. Current Topics in Medicinal Chemistry 2009, 9(15):1436-1446.
98. Tonoki A., Kuranaga E., Tomioka T., Hamazaki J., Murata S., Tanaka K., et al. Genetic evidence linking age-dependent attenuation of the 26S proteasome with the aging process. Molecular and Cellular Biology 2009, 29(4):1095-1106.
99. Tran P., Kim S.A., Choi H.S., Yoon J.H., Ahn S.G. Epigallocatechin-3-gallate suppresses the expression of HSP70 and HSP90 and exhibits anti-tumor activity in vitro and in vivo. BMC Cancer 2010, 10.
100. Walsh D.M., Selkoe D.J. A beta Oligomers - a decade of discovery. Journal of Neurochemistry 2007, 101(5):1172-1184.
101. Waza M., Adachi H., Katsuno M., Minamiyama M., Sang C., Tanaka F., et al. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nature Medicine 2005, 11(10):1088-1095.
102. Waza M., Adachi H., Katsuno M., Minamiyama M., Tanaka F., Sobue G. Alleviating neurodegeneration by an anticancer agent - An Hsp90 inhibitor (17-AAG). Integrated molecular medicine for neuronal and neoplastic disorders 2006, Blackwell Publishing, Boston, MA, (Vol. 1086, pp. 21-34). G. Sobue, M. Takahashi, J. Yoshida, K. Kaibuchi, T. Naoe, D.K. Lahiri (Eds.).
103. Westerheide S.D., Bosman J.D., Mbadugha B.N.A., Kawahara T.L.A., Matsumoto G., Kim S.J., et al. Celastrols as inducers of the heat shock response and cytoprotection. Journal of Biological Chemistry 2004, 279(53):56053-56060.
104. Yin Z.Y., Henry E.C., Gasiewicz T.A. (-)-Epigallocatechin-3-gallate is a novel Hsp90 inhibitor. Biochemistry 2009, 48(2):336-345.
105. Zhang B., Au Q.Y., Yoon I.S., Tremblay M.H., Yip G., Zhou Y.F., et al. Identification of small-molecule HSF1 amplifiers by high content screening in protection of cells from stress induced injury. Biochemical and Biophysical Research Communications 2009, 390(3):925-930.
106. Zhang T., Hamza A., Cao X.H., Wang B., Yu S.W., Zhan C.G., et al. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Molecular Cancer Therapeutics 2008, 7(1):162-170.
107. Zhang T., Li Y.Y., Yu Y.K., Zou P., Jiang Y.Q., Sun D.X. Characterization of celastrol to inhibit Hsp90 and Cdc37 interaction. Journal of Biological Chemistry 2009, 284(51):35381-35389.
108. Zhao H.P., Brandt G.E., Galam L., Matts R.L., Blagg B.S.J. Identification and initial SAR of silybin: An Hsp90 inhibitor. Bioorganic & Medicinal Chemistry Letters 2011, 21(9):2659-2664.
109. Zhou H.Y., Beevers C.S., Huang S.L. The targets of curcumin. Current Drug Targets 2011, 12(3):332-347.
110. Zou J.Y., Guo Y.L., Guettouche T., Smith D.F., Voellmy R. Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell 1998, 94(4):471-480.